AbbVie Acquisition +4.5%: AbbVie Bets Big on Apogee
Is AbbVie’s $10.9 billion Apogee deal a bold immunology masterstroke, or an expensive bet on future growth? Maik Kemper Editor in Chief The acquisition of Apogee further builds…
AbbVie MAVIRET Approval Gets EMA Backing for Acute HCV
Could AbbVie’s latest MAVIRET milestone become another quiet growth lever as investors look beyond its biggest blockbuster franchises? Maik Kemper Editor in Chief Conclusion In short, AbbVie MAVIRET…
AbbVie Earnings +4.5% Surge After Bullish Upgrade Shock
Are AbbVie Earnings and a surprise Bank of America upgrade signaling a new phase in the pharma giant’s post-Humira transition? Maik Kemper Editor in Chief Conclusion In summary,…
AbbVie Dermatology Data Boom at AAD 2026 Shocks Investors
Can AbbVie’s latest dermatology data at AAD 2026 really secure its post-Humira growth story in immunology? Maik Kemper Editor in Chief Our robust evidence across multiple clinical trials…